Fritextsökning
Artiklar per år
Innehållstyper
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other industries for inspiration and knowledge.
-
Bilden av Alzheimers – neurobiolog vid SU och KI får Lennart Nilssons pris
Med fascinerande bilder och filmer i 3D har han bidragit till ökad kunskap om allt från innerörats anatomi till sjukdomar som fettlever och Alzheimers. Nu tilldelas neurobiologen Csaba Adori 2024 års Lennart Nilsson Award.
-
Ranking: Top 10 highest-paid CEOs in pharma
It's nice to hear that things go well for others, right? Some of those who have done really well – at least financially – are listed here in the ranking of the best paid CEOs in Big Pharma 2023.
-
Danish obesity success causes recruitment problems in southern Sweden
The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.
-
EMA review confirms a risk of new cancer after CAR-T
CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be attached to the product information and patients to be followed up for life.
-
EMA-granskning bekräftar risk för ny cancer efter CAR-T
CAR-T-terapier mot cancer kan i sällsynta fall ge upphov till sekundära cancersjukdomar. Det slås nu fast av den europeiska läkemedelsmyndigheten EMA, som kräver att en varningstext bifogas behandlingarna, och att patienterna följs upp under resten av sina liv.
-
Toppnamn till Smartcellas styrelse
KI-professorn Anna Martling och Regina Fritsche-Danielson, vetenskaplig ledare för Astra Zenecas forskningsanläggning i Göteborg, tar bägge plats i biotech- och medtechbolaget Smartcellas styrelse.
-
Danska fetmasucccén ger rekryteringsproblem för sydsvenska läkemedelsbolag
Danska Novo Nordisks starka expansion drabbar sydsvenska företag som får allt svårare att konkurrera om attraktiv personal.
-
Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”
The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from ABBA songs, turns 30 this year. "There is great interest in Sweden and Swedish solutions globally," says Anna Redwood from Business Sweden.
-
Bio Europe intar Stockholm i höst – ”Det svenska ekosystemet tar nu tillfället i akt”
Den internationella life science-konferensen Bio Europe kommer i november för första gången till Sverige. Konferensen, vars program tar inspiration av ABBA-låtar, fyller i år 30. ”Det finns ett stort intresse för Sverige och svenska lösningar globalt”, säger Anna Redwood från Business Sweden.
-
Setback for pharmaceutical companies in the Zantac case
A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.
-
Sofia Wallström is Lif's new CEO
Sofia Wallström has been appointed as the new CEO of the industry organization Lif, the trade association for the research-based pharmaceutical industry in Sweden.
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.
-
Mycket fokus på FoU hos Roche
Schweiziska Roche har läkemedelskandidater inom alltifrån onkologi till fetma och toppar när läkemedelsföretags pipelines listas. Ett skifte till ett allt större fokus på forskning och utveckling, menar Elin Gustavsson från Roche är en bidragande faktor.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what constitutes ‘fine research’.
-
Nya miljardbesparingar på Pfizer
Den amerikanske läkemedelsjätten Pfizer aviserar ett sparprogram som ska sänka bolagets kostnader med 1,5 miljarder dollar, motsvarande 16 miljarder kronor, under de kommande tre åren.
-
Samuel Lagercrantz: “Companies that do this successfully will take the lead”
The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that relieve pain or eliminate painful symptoms, writes Samuel Lagercrantz in an editorial.
-
Bayer has cut 1,500 roles – so far
German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.
-
Han är ny på Sahlgrenska Science Park
Mats Hellström är Sahlgrenska Science Parks nya Lab Manager. I hans nya roll ska han se över satsningen Health Innovation Labs.
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
Lundabolag får brittiskt miljonbidrag för blodtest
Lundabolaget Prolight Diagnostics har fått ett statligt brittiskt bidrag på 17 miljoner kronor för fortsatt utveckling av ett blodtest som ska upptäcka eller utesluta hjärtinfarkt.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politicians and royalty.